Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
University of Sao Paulo General Hospital
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07590219CT.gov Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity | — | Active Not Recruiting | — | — | — |
NCT06171152CT.gov Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues | — | Suspended | — | — | — |
NCT06201819CT.gov Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery | — | Completed | — | — | — |
NCT05285397CT.gov Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries. | — | Unknown | — | — | — |
NCT04643301CT.gov Liraglutide for Low-responders After Bariatric Surgery | — | Withdrawn | — | — | — |
NCT02616003CT.gov Preoperative Condition in Giant Obese Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Morbid Obesity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liraglutide (this asset) | University of Sao Paulo General Hospital | Approved | BB · 70 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Propofol | G.Gennimatas General Hospital | P4 | BBB |
| Chenodeoxycholic Acid | Hvidovre University Hospital | P4 | BBB |
| Colesevelam | Hvidovre University Hospital | P4 | BBB |
| Ramifentanyl | Hospital dos Lusíadas | P4 | BBB |
| Amoxicillin | Fatih Sultan Mehmet Training and Research Hospital | P4 | BBB |
| Semaglutide | Zuyderland Medisch Centrum | P4 | BBB |
| Omeprazole | Fatih Sultan Mehmet Training and Research Hospital | P4 | BB |
+42 more in the Morbid Obesity cohort
Other indications for Liraglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 84 |
| Type 1 Diabetes Mellitus | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liraglutide in Morbid Obesity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liraglutide-morbid-obesity-47657
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →